张力反应性增强子结合蛋白促进肝细胞癌发生、复发与转移
研究纳入296例接受根治性切除术的肝细胞癌(HCC)患者肿瘤及癌旁组织,分析张力反应性增强子结合蛋白(TonEBP)表达。92.6%患者肿瘤中TonEBP表达高于癌旁非肿瘤组织,且肿瘤与癌旁组织TonEBP表达可预测复发、转移和死亡。小鼠模型显示TonEBP通过细胞损伤与炎症、氧化应激诱导及刺激COX-2启动子三个共同位点促进肿瘤发生与生长。
要点
- 92.6%的HCC患者肿瘤组织TonEBP表达高于癌旁非肿瘤组织,与病因无关。
- 肿瘤及癌旁组织TonEBP表达在多变量分析中可预测复发、转移和死亡。
- TonEBP通过刺激COX-2启动子驱动其表达,参与HCC发生的共同通路。
核心结论
- TonEBP是HCC应对多种病因刺激时肿瘤发生与进展共同通路的关键组分,涉及通路多个步骤,是有吸引力的治疗靶点及预后生物标志物。
研究设计与样本
- 获取296例接受根治性切除术的HCC患者肿瘤及周围肝组织,用定量逆转录实时PCR(RT-PCR)和组织芯片免疫组化分析TonEBP表达。
- 使用TonEBP单倍体缺陷小鼠、肝细胞特异性及髓系特异性TonEBP缺失小鼠,并结合HCC及肝细胞系进行研究。
主要发现
- 92.6%的HCC患者肿瘤组织TonEBP表达高于癌旁非肿瘤组织,且与相关病因无关。
- 肿瘤及癌旁非肿瘤组织中TonEBP表达在多变量分析中预测复发、转移和死亡。
- TonEBP通过刺激启动子驱动环氧合酶-2(COX-2)表达。
- 小鼠HCC模型中,TonEBP响应不同病因刺激促进肿瘤发生与生长的三个共同作用位点为:细胞损伤与炎症、氧化应激诱导、刺激COX-2启动子。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hepatocellular carcinoma (HCC) is a common cancer with high rate of recurrence and mortality. Diverse aetiological agents and wide heterogeneity in individual tumours impede effective and personalised treatment. Tonicity-responsive enhancer-binding protein (TonEBP) is a transcriptional cofactor for the expression of proinflammatory genes. Although inflammation is intimately associated with the pathogenesis of HCC, the role of TonEBP is unknown. We aimed to identify function of TonEBP in HCC. DESIGN: Tumours with surrounding hepatic tissues were obtained from 296 patients with HCC who received completion resection. TonEBP expression was analysed by quantitative reverse transcription-quantitative real-time PCR (RT-PCR) and immunohfistochemical analyses of tissue microarrays. Mice with TonEBP haplodeficiency, and hepatocyte-specific and myeloid-specific TonEBP deletion were used along with HCC and hepatocyte cell lines. RESULTS: TonEBP expression is higher in tumours than in adjacent non-tumour tissues in 92.6% of patients with HCC regardless of aetiology associated. The TonEBP expression in tumours and adjacent non-tumour tissues predicts recurrence, metastasis and death in multivariate analyses. TonEBP drives the expression of cyclo-oxygenase-2 (COX-2) by stimulating the promoter. In mouse models of HCC, three common sites of TonEBP action in response to diverse aetiological agents leading to tumourigenesis and tumour growth were found: cell injury and inflammation, induction by oxidative stress and stimulation of the COX-2 promoter. CONCLUSIONS: TonEBP is a key component of the common pathway in tumourigenesis and tumour progression of HCC in response to diverse aetiological insults. TonEBP is involved in multiple steps along the pathway, rendering it an attractive therapeutic target as well as a prognostic biomarker.
引用
- Lee JH, Suh JH, Choi SY, et al. Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis. Gut. 2018. PMID: 29420225. doi:10.1136/gutjnl-2017-315348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。